Literature DB >> 24880106

Targeting mitochondrial dysfunction as in aging and glaucoma.

Neville N Osborne1, Claudia Núñez Álvarez2, Susana del Olmo Aguado2.   

Abstract

Neurons depend on their mitochondria for optimum function and become susceptible with age. Mitochondrial function is gradually impaired during aging because more electrons are converted to reactive oxygen species rather than being converted to ATP. Retinal ganglion cell mitochondria are additionally affected in glaucoma because of reduced oxygen delivery. Thus, targeting neuronal mitochondria to enhance their function as in glaucoma and aspects associated with aging provides potential ways of attenuating degenerating diseases. A substance worthy of mention is rapamycin, which affects regulated in development and DNA damage 1 (REDD1), and is known to enhance mitochondrial function. REDD1 appears to be prominent in retinal ganglion cells. An alternative exciting non-invasive approach is to use red light therapy that enhances mitochondrial function.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24880106     DOI: 10.1016/j.drudis.2014.05.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  18 in total

1.  The ultrastructure of rabbit sclera after scleral crosslinking with riboflavin and blue light of different intensities.

Authors:  Anett Karl; Felix N Makarov; Christian Koch; Nicole Körber; Carsten Schuldt; Martin Krüger; Andreas Reichenbach; Peter Wiedemann; Andreas Bringmann; Hans Peter Iseli; Mike Francke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-06       Impact factor: 3.117

Review 2.  Pharmacotherapy of glaucoma.

Authors:  Doreen Schmidl; Leopold Schmetterer; Gerhard Garhöfer; Alina Popa-Cherecheanu
Journal:  J Ocul Pharmacol Ther       Date:  2015-01-14       Impact factor: 2.671

3.  Impaired Purinergic Regulation of the Glial (Müller) Cell Volume in the Retina of Transgenic Rats Expressing Defective Polycystin-2.

Authors:  Stefanie Vogler; Thomas Pannicke; Margrit Hollborn; Matthias Kolibabka; Peter Wiedemann; Andreas Reichenbach; Hans-Peter Hammes; Andreas Bringmann
Journal:  Neurochem Res       Date:  2016-04-02       Impact factor: 3.996

4.  Blue Light Action on Mitochondria Leads to Cell Death by Necroptosis.

Authors:  Susana Del Olmo-Aguado; Claudia Núñez-Álvarez; Neville N Osborne
Journal:  Neurochem Res       Date:  2016-05-23       Impact factor: 3.996

Review 5.  Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future.

Authors:  Walter H Moos; Douglas V Faller; Ioannis P Glavas; David N Harpp; Michael H Irwin; Iphigenia Kanara; Carl A Pinkert; Whitney R Powers; Kosta Steliou; Demetrios G Vavvas; Krishna Kodukula
Journal:  Biores Open Access       Date:  2017-12-01

6.  Multifunctional Redox Modulators Protect Auditory, Visual, and Cognitive Function.

Authors:  Peter F Kador; Richard Salvi
Journal:  Antioxid Redox Signal       Date:  2021-08-13       Impact factor: 7.468

7.  Association of primary open-angle glaucoma with mitochondrial variants and haplogroups common in African Americans.

Authors:  David W Collins; Harini V Gudiseva; Benjamin Trachtman; Anita S Bowman; Anna Sagaser; Prithvi Sankar; Eydie Miller-Ellis; Amanda Lehman; Victoria Addis; Joan M O'Brien
Journal:  Mol Vis       Date:  2016-05-16       Impact factor: 2.367

8.  Measurement of Systemic Mitochondrial Function in Advanced Primary Open-Angle Glaucoma and Leber Hereditary Optic Neuropathy.

Authors:  Nicole J Van Bergen; Jonathan G Crowston; Jamie E Craig; Kathryn P Burdon; Lisa S Kearns; Shiwani Sharma; Alex W Hewitt; David A Mackey; Ian A Trounce
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

9.  Targeted Delivery of Mitochondrial Calcium Channel Regulators: The Future of Glaucoma Treatment?

Authors:  Leanne T Y Cheung; Abby L Manthey; Jimmy S M Lai; Kin Chiu
Journal:  Front Neurosci       Date:  2017-11-22       Impact factor: 4.677

10.  The MT-CO1 V83I Polymorphism is a Risk Factor for Primary Open-Angle Glaucoma in African American Men.

Authors:  David W Collins; Harini V Gudiseva; Venkata R M Chavali; Benjamin Trachtman; Meera Ramakrishnan; William T Merritt; Maxwell Pistilli; Rebecca A Rossi; Stephanie Blachon; Prithvi S Sankar; Eydie Miller-Ellis; Amanda Lehman; Victoria Addis; Joan M O'Brien
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-04-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.